Decision Letter: Request for Rotavirus vaccine support

Your Excellency,

I am writing in relation to Kyrgyzstan’s application for New Vaccines Support (NVS) for Rotavirus Programme, which was submitted to the Gavi Secretariat in September 2017.

In November 2017, the Independent Review Committee (IRC) reviewed your request and recommended approval subject to clarifications. Based on the country’s response to clarifications, the IRC recommended approval of the Rotavirus vaccine support to the country, subject to conditions and requirements as described in Annex A to this letter.

In February 2019, Gavi’s Secretariat took note of Kyrgyzstan’s request to switch vaccine preference from Rotarix, RV1, in plastic tubes to Rotasil, RV5, 2 doses per vial, lyophilised, due to the current supply disruption of Rotarix.

For any question or requests for additional information, please feel free to contact the Senior Country Manager, Ms Jamilya Sherova at jsherova@gavi.org.

Yours sincerely,

Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
The Director of Medical Services
Director Planning Unit, MoH
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
UNICEF Supply Division
Annex A

Decision Letter -
The Republic of Kyrgyzstan - Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Kyrgyzstan

2. Grant number: 1921-KGZ-13f-X
   Vaccine Introduction Grant number: 19-KGZ-08b-Y

3. Date of Decision Letter: 19/03/2019

4. Date of the Partnership Framework Agreement: 16/05/2014

5. Programme title: New Vaccine Support (NVS), Rotavirus Routine

6. Vaccine type: Rotavirus

7. Requested product presentation and formulation of vaccine: Rotasili, RV5, 2 doses per vial, lyophilised

8. Programme duration: 2019 - 2021

9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)

<table>
<thead>
<tr>
<th>Programme Budget (US$)</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>Total²</th>
</tr>
</thead>
<tbody>
<tr>
<td>US$432,500</td>
<td>US$553,500</td>
<td>US$682,000</td>
<td>US$1,668,000</td>
<td></td>
</tr>
</tbody>
</table>


11. Product switch grant: Not applicable

12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)³

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Rotavirus vaccines doses</td>
<td>278,800</td>
<td>357,000</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>US$432,500</td>
<td>US$553,500</td>
</tr>
</tbody>
</table>

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable


   According to the co-financing policy, the Country falls within the group Preparatory transition.

   The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>63,500</td>
<td>96,700</td>
<td>142,800</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>US$98,314</td>
<td>US$149,860</td>
<td>US$221,295</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>US$98,500</td>
<td>US$150,000</td>
<td>US$221,500</td>
</tr>
</tbody>
</table>

16. Operational support for campaigns: Not applicable

¹ This is the entire duration of the Programme.
² This is the total amount endorsed by Gavi for the entire duration of the Programme.
³ This is the amount that Gavi has approved.
17. **Additional reporting requirements:** Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

<table>
<thead>
<tr>
<th>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>• vaccine stock levels including buffer stock, by end of March;</td>
<td>31 March 2019</td>
</tr>
<tr>
<td>• number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</td>
<td>15 May 2019</td>
</tr>
</tbody>
</table>

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.                                                                 | To be agreed with Secretariat |

18. **Financial clarifications:** Not applicable

19. **Other conditions:** Not applicable

Signed by,

[Signature]

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
19th of March, 2019